| GSK-3β及β-catenin的表达定位与肺腺癌顺铂耐药作用机制研究 |
| |
| 引用本文： | 高原,陈奇,刘春英,王哲,李庆昌. GSK-3β及β-catenin的表达定位与肺腺癌顺铂耐药作用机制研究[J]. 肿瘤防治研究, 2015, 42(10): 960-964. DOI: 10.3971/j.issn.1000-8578.2015.10.002 |
| |
| 作者姓名： | 高原 陈奇 刘春英 王哲 李庆昌 |
| |
| 作者单位： | 1. 110847 沈阳，辽宁中医药大学病理教研室；2. 110179 沈阳，辽宁省体育科学研究所生理研究室；3. 110001 沈阳，中国医科大学病理教研室 |
| |
| 基金项目： | 国家自然科学基金（81403303）；辽宁省教育厅科学研究项目（L2012333）；中国博士后科学基金（2014M551122） |
| |
| 摘 要： | 目的 研究人肺腺癌细胞系A549和其顺铂耐药细胞系A549/DDP中GSK-3β及β-catenin的表达定位差异，以探讨其与肺腺癌顺铂耐药的作用机制。方法 MTT法检测A549和A549/DDP细胞对顺铂的IC50 ；免疫细胞荧光法检测顺铂处理前后两种细胞GSK-3β及β-catenin的定位表达。结果 顺铂对A549/DDP细胞的IC50值为（28.984±1.404）μmol/L高于A549细胞的（5.888±0.338）μmol/L（t=27.696，P<0.001）；A549/DDP细胞中的GSK-3β表达主要在胞质，顺铂处理后GSK-3β定位在胞质和胞核；β-catenin表达主要在胞膜、胞质，顺铂处理后定位转移至胞核。而A549细胞中GSK-3β及β-catenin表达定位无变化。结论 肺腺癌顺铂耐药的机制可能与GSK-3β胞质和胞核共同定位、β-catenin核转移定位相关。
|
| 关 键 词： | 肺肿瘤；化疗耐药；糖原合成激酶3&beta ；&beta -连环蛋白 |
| 收稿时间： | 2015-01-05 |
Mechanism of GSK-3β and β-catenin Expression Localization Mediating Cisplatinresistance of Lung Adenocarcinoma |
| |
| GAO Yuan,CHEN Qi,LIU Chunying,WANG Zhe,LI Qingchang. Mechanism of GSK-3β and β-catenin Expression Localization Mediating Cisplatinresistance of Lung Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(10): 960-964. DOI: 10.3971/j.issn.1000-8578.2015.10.002 |
| |
| Authors: | GAO Yuan CHEN Qi LIU Chunying WANG Zhe LI Qingchang |
| |
| Affiliation: | 1. Department of Pathology, Liaoning University of Chinese Traditional Medicine, Shenyang 110847, China; 2. Institute of Physiology, Liaoning Sports Science Institute, Shenyang 110179, China; 3. Department of Pathology, China Medical University, Shenyang 110001, China |
| |
| Abstract: | Objective To explore the mechanism of cisplatin-resistance of lung adenocarcinoma by evaluating the differences of GSK-3β and β-catenin expression localization in lung adenocarcinoma cell line A549 and its cisplatin resistance cell line A549/DDP. Methods MTT assay was used to determine IC50 values of cisplatin in A549 and A549/DDP cells. Immunofluorescence method was used to detect GSK-3β and β-catenin expression localization. Results IC50 value of cisplatin in A549/DDP cells was (28.984±1.404) μmol/L, higher than (5.888±0.338)μmol/L in A549 cells(t=27.696, P<0.001). GSK-3β expression localization in A549/DDP cell was mainly in the cytoplasm, while cisplatin changed its location to cytoplasm and nucleus. β-Catenin expression localization in A549/DDP cell was mainly in the membrance and cytoplasm, while cisplatin changed its location from cytoplasm to nuclear. However, GSK-3β and β-catenin expression localization in A549 cells had no change. Conclusion The mechanism of cisplatin-resistance of lung adenocarcinoma may be related to co-location of GSK-3β in cytoplasm and nucleus, and β-catenin location from cytoplasm to nuclear. |
| |
| Keywords: | Lung cancer Chemotheraphy resistance Glycogen synthesis kinase(GSK-3β) β-catenin |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
